„Compliant 2006“ – The value of valproate granules in the therapy of patients with epilepsy. An observational study in 272 patients

Background: Sodium valproate is available as a modified-release formulation consisting of tasteless granules (VPA-G, Ergenyl® Chronosphere®). It has been postulated that this formulation potentially reduces adverse events, improves the convenience of intake (once-daily dosage regimen) having a positive effect on compliance, which may lead to an increased clinical effectiveness. To challenge this hypothesis a prospective, post marketing surveillance in patients with epilepsy was conducted. Patients and Methods: 272 patients with epilepsy (44.5% women, mean age 44.8 (1–94) years, 64% younger than 50 years) were in…